Sara Núñez-García is Co-Founder and Partner at Forty51 Ventures, she sets the firm’s strategy and leads its portfolio management. Previously, Sara served as VP Investments at Roivant where she led investments and divestments across several therapeutic areas in the Biotech space. Earlier, Sara served as Principal with Sofinnova Partners where she supported and led over 10 venture investments in the Biotech space. Prior to her investment career, Sara spent 10 years in R&D including several years in the Pharma industry as a medicinal chemist where she contributed to the nomination of several clinical candidates, and a fellowship in Biochemistry/Biophysics at the Albert Einstein College of Medicine in New York. Sara received her PhD in Organic chemistry from the University of Manchester UK and she also holds an MBA from INSEAD.

Sascha Oliver Bucher is Co-Founder and Partner at Forty51 Ventures, he leads the firm’s deal making activities, as well as the operating activities of Forty51’s venture building model. Previously, he was Partner and Managing Director of Investments at Roivant and Head of Europe. Before that he went through the ranks at Roche with numerous Investment and Corporate Development functions including as Deputy Head of Global M&A. He was involved in 100+ transactions and negotiated and closed over 50 international deals with an accumulated total deal value of more than 10 billion USD. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel and is both a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager.

Tamas Schweighoffer is Co-Founder and Partner at Forty51 Ventures, he leads the firms scientific and medical evaluation of investment opportunities. Previously, he was Chief Scientific Officer at Alentis Therapeutics and has accumulated over 25 years of experience as a physician-scientist and translational pharma developer across multiple indications and modalities, both in academia, public and private research institutes, and in Pharma organizations. He has initiated and led more than 30 R&D projects, from original scientific discoveries up to proof of concept in man and significantly contributed to three medicines that reached the market. Tamas received his MD from the Semmelweis University Medical School in Budapest, Hungary.

Forty51 Ventures is a Biotech venture capital fund focused on creating companies around high-quality assets and indications that are often contrarian or overlooked.